Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A Boost for Radiation Therapy

03.11.2005


Does a combination of radiation therapy and the inhibition of integrins (key molecules in angiogenesis) improve the chance of cure in cancer?



An increasing number of cancer patients are cured today by radiation therapy – alone or in combination with surgery or chemotherapy. At the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), scientists of the Clinical Cooperation Unit “Radiation Oncology” headed by Professor Dr. Dr. Peter Huber are identifying ways to further enhance the effectiveness of this type of treatment. The research team is targeting a weak point of the tumor: the formation of new blood vessels, or angiogenesis.

Once a tumor has reached pinhead size, it needs a supply of blood by blood vessels. If this supply is cut off, tumor growth comes to a halt. To suppress the formation of new blood vessels, integrins are a suitable target. This protein family comprises about 20 members that are involved in cell-cell interaction and regulate contacts with the surrounding protein matrix. Integrins play a key role in the formation of new blood vessels.


The Heidelberg researchers have now tested a combination of radiotherapy and a drug named S247, a substance which specifically inhibits the function of integrins. Investigations in the culture dish have shown that the combination therapy is considerably more effective both against tumor cells and against blood vessel-forming endothelial cells than irradiation alone. The combination approach has also been tested in mice with transplanted human tumors (glioblastoma, skin and prostate cancer). In these experiments, the combined treatment slowed down tumor growth – with no noticeable toxicity – more than twice as much as either of the therapies alone. In addition, tumors in animals treated by the combination approach formed significantly less blood vessels.

The Heidelberg researchers were able to show that the synergistic effect of the combination treatment can be ascribed to the fact that integrin inhibition neutralizes the angiogenesis-promoting effect of radiation. As a survival strategy, endothelial cells respond to radiation by increasing their integrin production. This promotes their invasion of the tumor tissue. The S247 substance counteracts this effect, while at the same time promoting programmed cell of endothelial cells.

The researchers are now working to define the optimum time period between administration of the drug and irradiation. In a next step, they will carry out clinical studies to investigate whether integrin inhibitors also enhance the chances of cure in patients treated for cancer.

The task of the Deutsches Krebsforschungszentrum in Heidelberg (German Cancer Research Center, DKFZ) is to systematically investigate the mechanisms of cancer development and to identify cancer risk factors. The results of this basic research are expected to lead to new approaches in the prevention, diagnosis and treatment of cancer. The Center is financed to 90 percent by the Federal Ministry of Education and Research and to 10 percent by the State of Baden-Wuerttemberg. It is a member of the Helmholtz Association of National Research Centers (Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V.).

Julia Rautenstrauch | alfa
Further information:
http://www.dkfz.de/de/strahlentherapie/index.html

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>